The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region
2015
Abstract
Incidence of tuberculosis (TB) across certolizumab pegol (CZP) clinical trials in rheumatoid arthritis (RA), psoriasis, psoriatic arthritis and axial spondyloarthritis is reported, before and after the introduction of stricter TB screening. 44 TB cases were confirmed in pooled CZP RA trials (IR 0.47/100PY, patient-years). Implementation of more stringent LTBI screening, plus treatment for LTBI, reduced the IR of TB, even when INH was administered after starting CZP therapy